CU20170084A7 - COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC - Google Patents
COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxCInfo
- Publication number
- CU20170084A7 CU20170084A7 CUP2017000084A CU20170084A CU20170084A7 CU 20170084 A7 CU20170084 A7 CU 20170084A7 CU P2017000084 A CUP2017000084 A CU P2017000084A CU 20170084 A CU20170084 A CU 20170084A CU 20170084 A7 CU20170084 A7 CU 20170084A7
- Authority
- CU
- Cuba
- Prior art keywords
- compounds
- isoxazol
- acid compounds
- hydroxamic acid
- lpxc inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>Esta invención se refiere en general a compuestos de Fórmula I tal como se describen en el presente documento y composiciones que contienen dichos compuestos, así como métodos de uso de dichos compuestos para tratar infecciones bacterianas. En ciertos aspectos, Ia invención proporciona métodos y composiciones que comprenden estos compuestos para el tratamiento de infecciones causadas por bacterias Gram negativas.</p> <p>ESPACIO PARA FÓRMULA<br /> </p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462092402P | 2014-12-16 | 2014-12-16 | |
| PCT/IB2015/059631 WO2016097995A1 (en) | 2014-12-16 | 2015-12-15 | Isoxazole hydroxamic acid compounds as lpxc inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20170084A7 true CU20170084A7 (es) | 2017-11-07 |
| CU24443B1 CU24443B1 (es) | 2019-10-04 |
Family
ID=55025302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2017000084A CU24443B1 (es) | 2014-12-16 | 2015-12-15 | COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC |
Country Status (42)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200527A1 (es) | 2013-05-17 | 2020-03-09 | Incyte Corp | Derivados del bipirazol como inhibidores jak |
| HRP20201524T1 (hr) * | 2016-06-14 | 2021-03-05 | Novartis Ag | Kristalni oblik (r)-4-(5-(ciklopropiletinil) izoksazol-3 -il)-n-hidroksi-2-metil-2-(metilsufonil) butanamid kao antibakterijsko sredstvo |
| CN107434766A (zh) * | 2017-08-09 | 2017-12-05 | 凯莱英医药集团（天津）股份有限公司 | 烷烃羟胺类化合物的合成装置及连续合成方法 |
| UA127519C2 (uk) | 2018-02-16 | 2023-09-20 | Інсайт Корпорейшн | Інгібітори шляху jak1, призначені для лікування порушень, пов'язаних із цитокінами |
| CA3113226A1 (en) | 2018-09-20 | 2020-03-26 | Forge Therapeutics, Inc. | Antibacterial compounds |
| TW202039478A (zh) * | 2018-11-21 | 2020-11-01 | 日商大正製藥股份有限公司 | 新穎咪唑衍生物 |
| JP7802696B2 (ja) | 2020-06-02 | 2026-01-20 | インサイト・コーポレイション | Ｊａｋ１阻害剤の調製プロセス |
| JP2023552452A (ja) | 2020-12-08 | 2023-12-15 | インサイト・コーポレイション | 白斑治療用のｊａｋ１経路阻害薬 |
| CN112603936B (zh) * | 2020-12-28 | 2022-08-02 | 仲恺农业工程学院 | 一种抑制气单胞菌属的组合物及其制备方法与应用 |
| WO2022173756A1 (en) * | 2021-02-11 | 2022-08-18 | Forge Therapeutics, Inc. | Antibacterial compounds |
| TW202246218A (zh) * | 2021-02-11 | 2022-12-01 | 美商福吉醫療公司 | 抗菌化合物 |
| EP4696710A3 (en) | 2021-05-03 | 2026-05-06 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of prurigo nodularis |
| CA3233328A1 (en) * | 2021-09-28 | 2023-04-06 | Min Teng | Lpxc inhibitors and uses thereof |
| WO2024067812A1 (zh) * | 2022-09-28 | 2024-04-04 | 浙江海正药业股份有限公司 | 芳香乙炔类衍生物及其制备方法和用途 |
| US20260092055A1 (en) * | 2022-09-28 | 2026-04-02 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Aromatic Acetylene Derivative, Preparation Method Therefor, And Pharmaceutical Use Thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3381783D1 (de) | 1982-03-03 | 1990-09-13 | Genentech Inc | Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen. |
| DE59009528D1 (de) | 1989-09-22 | 1995-09-21 | Basf Ag | Carbonsäureamide. |
| DE69738749D1 (de) | 1996-08-16 | 2008-07-17 | Schering Corp | Zelloberflächen-antigen aus säugetieren und verwandte reagenzien |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| WO1999020758A1 (en) | 1997-10-21 | 1999-04-29 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
| JP2002502607A (ja) | 1998-02-09 | 2002-01-29 | ジェネンテク・インコーポレイテッド | 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸 |
| PT1196186E (pt) | 1999-07-12 | 2008-02-14 | Genentech Inc | Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral. |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| SG159388A1 (en) | 2003-01-08 | 2010-03-30 | Chiron Corp | Antibacterial agents |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2004244626A1 (en) | 2003-05-23 | 2004-12-09 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| US20050048054A1 (en) | 2003-07-11 | 2005-03-03 | Shino Hanabuchi | Lymphocytes; methods |
| WO2005055808A2 (en) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| US20060002932A1 (en) | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| GB0502418D0 (en) | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| CN101801413A (zh) | 2007-07-12 | 2010-08-11 | 托勒克斯股份有限公司 | 采用gitr结合分子的联合疗法 |
| RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| KR20110044992A (ko) | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＧＦ-β 길항제 다중-표적 결합 단백질 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| CN102149820B (zh) | 2008-09-12 | 2014-07-23 | 国立大学法人三重大学 | 能够表达外源gitr配体的细胞 |
| US8722686B2 (en) * | 2008-09-19 | 2014-05-13 | Pfizer Inc. | Hydroxamic acid derivatives useful as antibacterial agents |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| PT3023438T (pt) | 2009-09-03 | 2020-05-08 | Merck Sharp & Dohme | Anticorpos anti-gitr |
| CA2774250C (en) * | 2009-10-13 | 2013-12-17 | Pfizer Inc. | C-linked hydroxamic acid derivatives useful as antibacterial agents |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| PL2512474T3 (pl) * | 2009-12-16 | 2015-03-31 | Pfizer | N-przyłączone pochodne kwasu hydroksamowego użyteczne jako środki przeciwbakteryjne |
| SI2519543T1 (sl) | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| US8877754B2 (en) | 2010-09-06 | 2014-11-04 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| AR083760A1 (es) | 2010-11-10 | 2013-03-20 | Achaogen Inc | Agentes antibacterianos y composiciones farmaceuticas |
| GEP20156370B (en) | 2011-03-07 | 2015-09-25 | Pfizer | Fluoro-pyridinone derivatives useful as antibacterial agents |
| EP2694488B1 (en) * | 2011-04-08 | 2014-11-12 | Pfizer Inc | Isoxazole derivatives useful as antibacterial agents |
| EP2694481B1 (en) * | 2011-04-08 | 2015-12-30 | Pfizer Inc | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| WO2014160649A1 (en) | 2013-03-29 | 2014-10-02 | Novartis Ag | Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections |
-
2015
- 2015-12-15 CU CU2017000084A patent/CU24443B1/es unknown
- 2015-12-15 AU AU2015365455A patent/AU2015365455B2/en not_active Ceased
- 2015-12-15 LT LT15816893T patent/LT3233843T/lt unknown
- 2015-12-15 PT PT158168930T patent/PT3233843T/pt unknown
- 2015-12-15 US US14/969,930 patent/US9549916B2/en not_active Expired - Fee Related
- 2015-12-15 PE PE2017001078A patent/PE20171044A1/es unknown
- 2015-12-15 WO PCT/IB2015/059631 patent/WO2016097995A1/en not_active Ceased
- 2015-12-15 SI SI201530987T patent/SI3233843T1/sl unknown
- 2015-12-15 EA EA201791353A patent/EA032138B1/ru not_active IP Right Cessation
- 2015-12-15 ES ES15816893T patent/ES2756300T3/es active Active
- 2015-12-15 PL PL15816893T patent/PL3233843T3/pl unknown
- 2015-12-15 MX MX2017007980A patent/MX2017007980A/es active IP Right Grant
- 2015-12-15 ME MEP-2019-305A patent/ME03546B/me unknown
- 2015-12-15 TN TN2017000207A patent/TN2017000207A1/en unknown
- 2015-12-15 MY MYPI2017701741A patent/MY195743A/en unknown
- 2015-12-15 TW TW104142164A patent/TWI693215B/zh not_active IP Right Cessation
- 2015-12-15 EP EP15816893.0A patent/EP3233843B1/en active Active
- 2015-12-15 UA UAA201705042A patent/UA121225C2/uk unknown
- 2015-12-15 SG SG11201704053WA patent/SG11201704053WA/en unknown
- 2015-12-15 CR CR20170260A patent/CR20170260A/es unknown
- 2015-12-15 CA CA2969803A patent/CA2969803A1/en not_active Abandoned
- 2015-12-15 MA MA41185A patent/MA41185B1/fr unknown
- 2015-12-15 HU HUE15816893A patent/HUE047225T2/hu unknown
- 2015-12-15 HR HRP20192009TT patent/HRP20192009T1/hr unknown
- 2015-12-15 SM SM20190631T patent/SMT201900631T1/it unknown
- 2015-12-15 DK DK15816893T patent/DK3233843T3/da active
- 2015-12-15 JP JP2017532143A patent/JP6697466B2/ja not_active Expired - Fee Related
- 2015-12-15 RS RS20191403A patent/RS59507B1/sr unknown
- 2015-12-15 KR KR1020177016102A patent/KR20170094214A/ko not_active Withdrawn
- 2015-12-15 CN CN201580066726.8A patent/CN107001295B/zh not_active Expired - Fee Related
- 2015-12-15 BR BR112017011422-4A patent/BR112017011422A2/pt not_active IP Right Cessation
- 2015-12-16 AR ARP150104119A patent/AR107428A1/es unknown
- 2015-12-16 UY UY0001036448A patent/UY36448A/es not_active Application Discontinuation
- 2015-12-16 JO JOP/2015/0318A patent/JO3818B1/ar active
-
2016
- 2016-12-12 US US15/375,560 patent/US9815804B2/en not_active Expired - Fee Related
-
2017
- 2017-05-18 IL IL25237317A patent/IL252373B/en active IP Right Grant
- 2017-06-01 PH PH12017501019A patent/PH12017501019B1/en unknown
- 2017-06-08 CL CL2017001460A patent/CL2017001460A1/es unknown
- 2017-06-14 CO CONC2017/0005870A patent/CO2017005870A2/es unknown
- 2017-06-16 GT GT201700132A patent/GT201700132A/es unknown
- 2017-06-16 SV SV2017005462A patent/SV2017005462A/es unknown
- 2017-07-16 EC ECIEPI201745737A patent/ECSP17045737A/es unknown
- 2017-10-09 US US15/728,351 patent/US10029994B2/en active Active
-
2019
- 2019-11-11 CY CY20191101181T patent/CY1122305T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017005870A2 (es) | Compuestos de isoxazol de ácido hidroxámico como inhibidores de lpxc | |
| SV2016005274A (es) | Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas | |
| EA201391072A1 (ru) | Производные фтор-пиридинона, полезные в качестве антибактериальных агентов | |
| MX2013011526A (es) | Derivados de isoxazol utiles como agentes antibacteriales . | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| MX389771B (es) | Compuestos de minociclina para biodefensas. | |
| CL2017000484A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| PH12015502032A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MX2017004632A (es) | Mejoras en y relacionadas con el tratamiento del agua, en particular para inhibir el crecimiento de microorganismos. | |
| UY36043A (es) | COMPUESTOS ORGÁNICOS DE MONOBACbTAM PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS | |
| CR20160412A (es) | Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas |